Drug intelligence / Profile preview

NI-2101

Development stage: Preclinical
Lead developer: Lightchain Bioscience
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

NI-2101 is a fully human bispecific IgG antibody that targets both activated coagulation factor IX (FIXa) and factor X (FX). It is being developed for the treatment of hemophilia A. The drug acts as an inhibitor of both FIXa and FX, key enzymes in the blood coagulation cascade. By inhibiting these factors, NI-2101 aims to modulate clotting activity in patients with bleeding disorders such as hemophilia A. The drug was originally developed by Light Chain Bioscience (formerly Novimmune) and has been co-developed with Takeda[1][2][9].

Targets

F10 (Factor Xa)Coagulation Factor IXa

Beyond the preview

Go deeper on NI-2101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NI-2101.

Explore the full profile